Baxter International Inc (BAX) : Lipe Dalton reduced its stake in Baxter International Inc by 0.46% during the most recent quarter end. The investment management company now holds a total of 85,905 shares of Baxter International Inc which is valued at $3.9 Million after selling 400 shares in Baxter International Inc , the firm said in a disclosure report filed with the SEC on May 12, 2016.Baxter International Inc makes up approximately 3.06% of Lipe Dalton’s portfolio.
Other Hedge Funds, Including , Bb&t Securities boosted its stake in BAX in the latest quarter, The investment management firm added 171,665 additional shares and now holds a total of 383,629 shares of Baxter International Inc which is valued at $17.5 Million. Baxter International Inc makes up approx 0.29% of Bb&t Securities’s portfolio. Shufro Rose Co sold out all of its stake in BAX during the most recent quarter. The investment firm sold 99,690 shares of BAX which is valued $4.5 Million.Birch Hill Investment Advisors reduced its stake in BAX by selling 18,110 shares or 34.27% in the most recent quarter. The Hedge Fund company now holds 34,738 shares of BAX which is valued at $1.6 Million. Baxter International Inc makes up approx 0.16% of Birch Hill Investment Advisors’s portfolio.Hendershot Investments reduced its stake in BAX by selling 1,021 shares or 1.32% in the most recent quarter. The Hedge Fund company now holds 76,598 shares of BAX which is valued at $3.5 Million. Baxter International Inc makes up approx 1.77% of Hendershot Investments’s portfolio.
Baxter International Inc closed down -0.24 points or -0.56% at $42.92 with 1,16,81,644 shares getting traded on Friday. Post opening the session at $43.35, the shares hit an intraday low of $42.89 and an intraday high of $43.51 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Baxter International Inc reported $0.36 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.29. The company had revenue of $2375.00 million for the quarter, compared to analysts expectations of $2351.22 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.00 EPS.
Investors should note that on May 3, 2016, Baxter International Inc announced a cash dividend of $0.1300. The company’s management has announced Jun 1, 2016 as the ex-dividend date and fixed the record date on Jun 3, 2016. The payable date has been fixed on Jul 1, 2016.
Many Wall Street Analysts have commented on Baxter International Inc. Company shares were Reiterated by RBC Capital Mkts on Apr 27, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 47 from a previous price target of $40 .Baxter International Inc was Upgraded by Piper Jaffray to ” Overweight” on Apr 14, 2016.
Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment which include three commercial franchises: Hemophilia BioTherapeutics and BioSurgery and Medical Products segment which include four commercial franchises: Fluid Systems Renal Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute blood-related conditions and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets premixed drugs and drug-reconstitution systems pre-filled vials and syringes for injectable drugs IV nutrition products infusion pumps and inhalation anesthetics. Its products are used in hospitals kidney dialysis centers and nursing homes among others.